General information
  • Disease category Hematologic diseases (non cancer) (BASEC)
  • Recruitment status recruitment not started yet (BASEC/ICTRP)
  • Trial sites
    Zurich
    (BASEC)
  • Contact Prof. Dr. Nicole Stoffel nicole.stoffel@pharma.ethz.ch (BASEC)
  • Data Source(s) BASEC: Import from 13.02.2026 ICTRP: N/A
  • Last update 13.02.2026 12:25
HumRes67753 | SNCTP000006774 | BASEC2025-00261

Absorption of Iron from Lactoferrin: A Study in Women with Iron Deficiency

  • Disease category Hematologic diseases (non cancer) (BASEC)
  • Recruitment status recruitment not started yet (BASEC/ICTRP)
  • Trial sites
    Zurich
    (BASEC)
  • Contact Prof. Dr. Nicole Stoffel nicole.stoffel@pharma.ethz.ch (BASEC)
  • Data Source(s) BASEC: Import from 13.02.2026 ICTRP: N/A
  • Last update 13.02.2026 12:25

Summary description of the study

We have developed new forms of lactoferrin, an iron-binding protein from milk, to treat iron deficiency. There are reasons to believe that these compounds represent an improvement over the iron compounds currently used to fortify foods with iron. The study will last 64 days. Each participant will come to the study center for a screening examination and, if enrolled in the study, will participate on 10 mornings. Participants will consume six test meals made from corn porridge and three from water, which contain the stabilized lactoferrin compounds and/or iron sulfate – one test meal per appointment. Each participant will go through all 9 test conditions. The iron compounds will be specifically labeled with stable isotopes, which are safe markers and allow researchers to track how much iron your body absorbs. To measure absorption, researchers will examine how much of the labeled iron is absorbed and used for the formation of new red blood cells 17 days later.

(BASEC)

Intervention under investigation

Iron Compounds

(BASEC)

Disease under investigation

Iron Deficiency

(BASEC)

Criteria for participation in trial
• Women • Age: 18–45 years • Serum ferritin levels below 45 µg/L (BASEC)

Exclusion criteria
• Women with hemoglobin levels below 12 g/dL (measured during the pre-examination) • Women with acute or chronic diseases that affect iron absorption and iron metabolism • Individuals taking long-term medications that affect iron absorption, iron metabolism, or gut health (BASEC)

Trial sites

Zurich

(BASEC)

not available

Sponsor

Laboratory of Clinical Biopharmacy, ETH Zurich

(BASEC)

Contact

Contact Person Switzerland

Prof. Dr. Nicole Stoffel

+41 44 632 8393

nicole.stoffel@pharma.ethz.ch

Institut für Pharmazeutische Wissenschaften

(BASEC)

Scientific Information

not available

Name of the authorising ethics committee (for multicentre studies, only the lead committee)

Ethics Committee Zurich

(BASEC)

Date of authorisation

30.01.2026

(BASEC)


ICTRP Trial ID
not available

Official title (approved by ethics committee)
Iron absorption from stabilized lactoferrin: an experimental study in iron-deficient women (LOBSTER) (BASEC)

Academic title
not available

Public title
not available

Disease under investigation
not available

Intervention under investigation
not available

Type of trial
not available

Trial design
not available

Inclusion/Exclusion criteria
not available

not available

Primary and secondary end points
not available

not available

Registration date
not available

Incorporation of the first participant
not available

Secondary sponsors
not available

Additional contacts
not available

Secondary trial IDs
not available

Results-Individual Participant Data (IPD)
not available

Further information on the trial
not available

Results of the trial

Results summary

not available

Link to the results in the primary register

not available